ATM heterozygosity and cancer risk
- 1 September 2002
- journal article
- Published by Springer Nature in Nature Genetics
- Vol. 32 (1), 89-90
- https://doi.org/10.1038/ng0902-89
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Dominant Negative ATM Mutations in Breast Cancer FamiliesJNCI Journal of the National Cancer Institute, 2002
- Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancerProceedings of the National Academy of Sciences, 2002
- Increased frequency ofATM mutations in breast carcinoma patients with early onset disease and positive family historyCancer, 2001
- Cancer risk in heterozygotes for ataxia-telangiectasiaInternational Journal of Cancer, 2001
- Cancer Risk in ATM Heterozygotes: A Model of Phenotypic and Mechanistic Differences between Missense and Truncating MutationsMolecular Genetics and Metabolism, 1999
- ATM Mutations and Phenotypes in Ataxia-Telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast CancerAmerican Journal of Human Genetics, 1998
- Heterozygous ATM mutations do not contribute to early onset of breast cancerNature Genetics, 1997
- Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancerCancer Genetics and Cytogenetics, 1996
- Incidence of Cancer in 161 Families Affected by Ataxia–TelangiectasiaNew England Journal of Medicine, 1991
- Breast and Other Cancers in Families with Ataxia-TelangiectasiaNew England Journal of Medicine, 1987